{"entity":{"id":"nct06431633","kind":"trial","name":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","aka":["ARIAN"],"tldr":"A phase 3 trial of zimberelimab, sacituzumab govitecan, cisplatin and carboplatin in lung cancer, run by Fundación GECP, now recruiting.","summary":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. is a phase 3, randomised interventional study registered as NCT06431633 by Fundación GECP, with a registry enrolment figure of 129 participants, started 2025-02-04 and due to reach its primary completion in 2031-11-30. Interventions recorded: Zimberelimab; Sacituzumab govitecan; Cisplatin; Carboplatin. Conditions listed: Lung Diseases; Carcinoma, Non-Small-Cell Lung; Resectable Lung Non-Small Cell Carcinoma. Primary outcome: Disease free survival. Lung eligibility wording from the registry: \"Patients diagnosed of primary non-small cell lung cancer, histologically confirmed\". Sites: Spain. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06431633","url":"https://clinicaltrials.gov/study/NCT06431633"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["zimberelimab","sacituzumab-govitecan","cisplatin","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06431633","phase":"3","setting":"A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA-IIIB(N2) Previously Resected (R0) Non-small Cell Lung Cancer Patients That Did Not Achieve Pathological Complete Response After Neoadjuvant treatment_ARIAN","sponsor":"Fundación GECP","enrolled":129,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06431633/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}